Toripalimab clinical trials
Also written JS001, Tuoyi, Loqtorzi and TAB001.
How each study uses toripalimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the toripalimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Oct 2023 · LOQTORZI · BLA 761240 (FDA, Drugs@FDA)
- European Union
- 19 Sept 2024 · Loqtorzi · EMEA/H/C/006120 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Other names
- Tripleitriumab
- 1
Studies by the year they started
361 studies that test it; most in 2020 (58); 1 more planned to start later
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 9 |
| 2019 | 47 |
| 2020 | 58 |
| 2021 | 48 |
| 2022 | 37 |
| 2023 | 40 |
| 2024 | 40 |
| 2025 | 36 |
| 2026 | 41 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 31 · Other 331
Sun Yat-sen University (52) · Shanghai Junshi Bioscience Co., Ltd. (33) · Fudan University (17) · Tianjin Medical University Cancer Institute and Hospital (12) · Peking University Cancer Hospital & Institute (11) · Peking University (8) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (8) · Peking Union Medical College Hospital (8)
Often tested with
Tested in the same studies.
Anlotinib (18) · Lenvatinib (12) · Surufatinib (11) · Cisplatin (9) · Paclitaxel (9) · Disitamab vedotin (9) · Gemcitabine (7) · Axitinib (6)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 5 phase 3 studies under way
Toripalimab is the comparator. A study of two new drugs counts under both.
- 1Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 · Shanghai Junshi Bioscience Co., Ltd. · next primary completion Oct 2029
- 1JS007 · Shanghai Junshi Bioscience Co., Ltd. · next primary completion Oct 2029
- 1Anlotinib · The First Affiliated Hospital of Zhengzhou University · next primary completion Dec 2028
- 1Benmelstobart · The First Affiliated Hospital of Zhengzhou University · next primary completion Dec 2028
- 1Nimotuzumab · Sun Yat-sen University · next primary completion Jul 2030
- 1Gemcitabine · Zhiquan Hu · next primary completion Jul 2028
- 1Trastuzumab rezetecan · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · next primary completion Mar 2028
- 1Adebrelimab · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · next primary completion Mar 2028
Reaching primary completion within a year · 41, 9 in phase 3
Studies that test toripalimab, phase 3 first.
- Dec 2026Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialPhase 3 · Sun Yat-sen University
- Dec 2026Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)Phase 3 · Shanghai Pulmonary Hospital, Shanghai, China
- Dec 2026Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical ResectionPhase 2/3 · Shanghai Junshi Bioscience Co., Ltd.
- Dec 2026Phase III Study of Toripalimab(JS001) Combined With Lenvatinib for Advanced HCCPhase 3 · Shanghai Junshi Bioscience Co., Ltd.
- Mar 2027Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)Phase 3 · First Affiliated Hospital of Zhejiang University
- May 2027Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaPhase 3 · Shanghai Junshi Bioscience Co., Ltd.
- May 2027Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III StudyPhase 3 · Shanghai Junshi Bioscience Co., Ltd.
- Jul 2027Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)Phase 3 · Shanghai Junshi Bioscience Co., Ltd.
- Sep 20279MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial CancerPhase 3 · Mabwell (Shanghai) Bioscience Co., Ltd.
- Nov 2026Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid TumorsPhase 1/2 · Guangzhou Medical University
Studies
Open first, then newest update. How each study uses toripalimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 362
- Efficacy and Safety Exploration of Short Course Radiotherapy Followed by Surufatinib and Toripalimab in Neoadjuvant Treatment of Locally Advanced Rectal CancerRecruitingPhase 2/3The First Hospital of Jilin UniversityNCT07935759Written as Toripalimab
- A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic CancerNot yet recruitingNot applicableRuijin HospitalNCT07928362Written as Toripalimab
- DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder CancerNot yet recruitingPhase 1Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07853053Written as Toripalimab
- Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal CarcinomaRecruitingPhase 2Affiliated Hospital of Guangdong Medical UniversityNCT07136519Written as Toripalimab
- Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II StudyRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07896681Written as Toripalimab
- Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerNot yet recruitingPhase 2Tianjin Medical University Second HospitalNCT07879469Written as Disitamab Vedotin and Toripalimab
- Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter StudyRecruitingPhase 3Tianjin Medical University Cancer Institute and HospitalNCT07246330Written as Toripalimab
- Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung CancerRecruitingPhase 1Second Xiangya Hospital of Central South UniversityNCT07886229Written as Toripalimab
- Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer SubjectsRecruitingPhase 2Zhujiang HospitalNCT04861584Written as Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin
- Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon CancerRecruitingPhase 2Emory UniversityNCT07140679Written as Toripalimab
- Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung CancerRecruitingPhase 2West China HospitalNCT07855965Written as Toripalimab
- PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCCNot yet recruitingPhase 2Vanderbilt-Ingram Cancer CenterNCT07836049Written as Toripalimab
- Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard TherapyRecruitingPhase 1Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07835035Written as Toripalimab
- MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary CarcinomasNot yet recruitingPhase 2Fudan UniversityNCT07816770Written as Toripalimab
- SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic SarcomaNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07817095Written as Toripalimab
- Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBTNot yet recruitingPhase 2Tianjin First Central HospitalNCT07808216Written as Toripalimab (JS001 )
- Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance StatusNot yet recruitingPhase 2Barbara Ann Karmanos Cancer InstituteNCT07796126Written as Toripalimab
- Toripalimab With Chemotherapy for Sinus CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT06940180Written as Toripalimab
- TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell CarcinomaNot yet recruitingPhase 2Fudan UniversityNCT07776717Written as Toripalimab
- Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast CancerRecruitingPhase 2Xijing HospitalNCT06914440Written as Toripalimab
See all 362 studies that test toripalimab →
Given beside what is tested · 134 — toripalimab is usual care or a partner of the new treatment
- Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian CancerRecruitingPhase 2Canadian Cancer Trials GroupNCT04918186Written as Toripalimab
- Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07922928Written as Toripalimab
- A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)RecruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT07876557Written as JS212 in combination with JS001
- Sacituzumab Tirumotecan Plus Toripalimab for Advanced Penile Cancer After Platinum ChemotherapyNot yet recruitingPhase 2Anhui Provincial HospitalNCT07907861Written as Toripalimab
- TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingPhase 1Metaclipse Therapeutics CorporationNCT07898124Written as Toripalimab-tpzi
- STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected SarcomasRecruitingPhase 1/2STORM Therapeutics LTDNCT06975293Written as STC-15 in combination with toripalimab
- A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.RecruitingPhase 1/2Nanjing Leads Biolabs Co.,LtdNCT07099430Written as Toripalimab Injection
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingPhase 2LaNova Medicines Zhejiang Co., Ltd.NCT05934331Written as Toripalimab
- PDT For Induction Therapy For Head And Neck CancerRecruitingPhase 2Massachusetts General HospitalNCT07214987Written as Toripalimab-tpzi
- Window of Opportunity in Preserving Laryngeal Function TrialRecruitingPhase 2Matthew SpectorNCT07423078Written as Toripalimab
- A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.RecruitingPhase 1/2Hangzhou DAC Biotechnology Co., Ltd.NCT07559929Written as Toripalimab
- Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid TumorsRecruitingPhase 1/2Suzhou Abogen Biosciences Co., Ltd.NCT06088004Written as Toripalimab
- Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 TherapyRecruitingPhase 1West China HospitalNCT07562841Written as Toripalimab
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid TumorsRecruitingPhase 1/2Wigen Biomedicine Technology (Shanghai) Co., Ltd.NCT06953323Written as WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab
- Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07823270Written as Toripalimab
- Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingPhase 2Shaodong HongNCT07819578Written as Toripalimab
- A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract CancerRecruitingPhase 4Xianglin YuanNCT07619235Written as Iparomlimab and Toripalimab
- Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 StudyNot yet recruitingPhase 2First Affiliated Hospital of Wenzhou Medical UniversityNCT07189793Written as Toripalimab
- Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck TumorsRecruitingPhase 1West China HospitalNCT07625423Written as EDS01 1.0×10^11 VP + Toripalimab
- A Phase I/II Study of LM-2417 in Subjects With Advanced Solid TumoursRecruitingPhase 1/2LaNova Medicines LimitedNCT06682780Written as Toripalimab/Tirelizumab
Showing 20 of 134.
As the comparator · 8 — what is tested is compared with toripalimab
- JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver CancerNot yet recruitingPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT07823348Written as Toripalimab
- Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal CarcinomaRecruitingPhase 3Sun Yat-sen UniversityNCT07706985Written as Toripalimab combined with Nimotuzumab
- Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBCRecruitingPhase 3Zhiquan HuNCT07693959Written as Toripalimab
- A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingPhase 3The First Affiliated Hospital of Zhengzhou UniversityNCT07446335Written as Toripalimab Combined with Chemotherapy
- A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast CancerRecruitingPhase 1/2Nanjing Leads Biolabs Co.,LtdNCT07281976Written as Toripalimab Injection
- A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07111832Written as Toripalimab Injection
- Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast CancerRecruitingPhase 2RemeGen Co., Ltd.NCT06642545Written as Toripalimab
- Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus unknownPhase 2Henan Cancer HospitalNCT04229849Written as Toripalimab
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting2
- Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal CarcinomaOct 29, 2026NCT07136519
- Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter StudyOct 23, 2026NCT07246330
Newly registered5
- Efficacy and Safety Exploration of Short Course Radiotherapy Followed by Surufatinib and Toripalimab in Neoadjuvant Treatment of Locally Advanced Rectal CancerNov 13, 2026NCT07935759
- A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic CancerNov 10, 2026NCT07928362
- Pre-Radiotherapy n-6/n-3 Fatty Acid Ratio Predicts Severe Oral Mucositis in Nasopharyngeal CarcinomaNov 5, 2026NCT07920250
- Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II StudyOct 27, 2026NCT07896681
- Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung CancerOct 21, 2026NCT07886229
Codes
What other systems call toripalimab · ClinicalTrials.gg INT001244
- MeSH (NLM) C000656314toripalimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8JXN261VVATORIPALIMABConfirmed FDA, NLM
- NCI Thesaurus C131334ToripalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000656314 | toripalimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8JXN261VVA | TORIPALIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C131334 | Toripalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.